pSivida Limited
pSivida is committed to the development of drug delivery products in the healthcare sector, initially in ophthalmology and oncology. pSivida has revenues from marketed products having developed the only two FDA approved sustained release back of the eye treatments for chronic eye disease and are licensed to Bausch & Lomb. Significant near-term revenues are expected from a diversified late-stage product portfolio including a next generation product licensed to Alimera Sciences for the treatment of Diabetic Macular Edema and Pfizer for all other ophthalmic applications. pSivida also owns the right to develop and commercialize a new biomaterial, nanostructured porous silicon (BioSilicon™), for multiple potential applications in healthcare with a core focus on drug delivery. pSivida's largest shareholder and strategic partner is Pfizer. QinetiQ (one of the largest R&D institutions in Europe) is pSivida's second largest shareholder.
Level 12, BGC Centre, 28 The Esplanade
Perth, WA 6000 Australia
+61 8 9226 5099
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||